The IMMUNOBIOGRAM® (IMBG) is an In Vitro Diagnostic (IVD) immunoassay that combines a biotechnological KIT and a software for data interpretation and to elaborate reports. There is no other product providing similar information.

IMBG offers a personalized comparative evaluation of the patient´s sensitivity/resistance profile to a panel of the most commonly used immunosuppressive drugs (IS) in clinical practice, allowing physicians to predict and monitor the response of patients‘ immune system cells to a specific IS. These cells are the target of all approved immunosuppressant therapies and is linked to drug efficacy.

Biohope has developed a clinical plan program to support the use of IMMUNOBIOGRAM® in Kidney Transplantation and Rheumatoid Arthritis, and it will be stepwise adapted and validated for other autoimmune diseases.


For the Physician

The IMMUNOBIOGRAM® provides information that will help physicians to personalize the immunosuppressive therapy in patients with inflammatory diseases, and help them to take informed decisions to select the most adequate immunosuppressive drugs (IS) for each patient to improve clinical outcomes.

For the Patient

In patients with renal transplant, an individualized immunosuppression regimen based on the patients´ immune cells response to IS can contribute notably to decrease graft rejection rates and to avoid the appearance of severe adverse events like metabolic disorders, opportunistic infections or malignancies.

Final Report IMBG RT

In patients with rheumatoid arthritis, the IMBG would help physicians to personalize the immunosuppressive therapy (IS) in patients with  Rheumatoid Arthritis (RA) to reach clinical remission and reduce the side effects of treatment (40% of patients will develop some type of functional disability after 10 years of evolution).

For Health Care providers

The use of the IMBG would entail a:

  • potential risk reduction of graft failure, with costs savings of € 20,279 (95% CI € 17,512-23,105)  per high-risk transplanted patient patient in 5 years.
  • potential reduction in the AE rate that would generate savings per non-high risk patient in 5 years of € 3,328 (95% CI € 451-7,957).


It is a simple process for the patient and for the physician. From the patient it is required a 10 ml peripheral blood sample, and the physician can request the IMMUNOBIOGRAM®, along with other tests, during the routinely follow-up visits.

The clinical lab perform the test, raw data is sent to Biohope, and the patient´s report is sent back to the physician.


The value of the IMBG relies on the design of a biomodel that:

  • Simplifies considerably the immunosuppressant therapy evaluation in terms of handling, costs and time.
  • Builds reliable dose/response curves
  • Adds precision, robustness, and standardization

Altogether, IMBG has become an innovative in vitro immune assay that combines a biotechnological kit and a software for data interpretation that currently cannot be duplicated in a normal reference lab, unless having access to all the biotechnological and mathematical development proven by Biohope.

Read more about me